Seeking Alpha

arthurs1

arthurs1
Send Message
View as an RSS Feed
View arthurs1's Comments BY TICKER:
Latest  |  Highest rated
  • Isis - Addressing Some Of The Bull Arguments To My Short Thesis [View article]
    Market doc has never been heard from since. His career as a financial writer ended appropriately with this specious article. He deserves all the blame and ignominy that befalls him.
    RIP

    ISIS hit an all time high today.
    Dec 11, 2014. 10:05 PM | Likes Like |Link to Comment
  • Isis - Addressing Some Of The Bull Arguments To My Short Thesis [View article]
    Hope no one listened to this pretend doctor. ISIS up almost 100% since this non scientifically based short hack job.
    Dec 11, 2014. 09:58 AM | 1 Like Like |Link to Comment
  • Regulus To See Further Declines [View article]
    This is not the only drug in development as you stated. I would not want to be short when the next data point comes out (multi dosing at higher dose). One dose of the Regulus drug versus how many for Harvoni? 84! Double that with cirrhosis. Not a very fair comparison. Insurance companies would love the cheaper drug.
    Nov 19, 2014. 08:27 PM | 1 Like Like |Link to Comment
  • Regulus To See Further Declines [View article]
    Characterization of the in vitro antiviral activity and the preclinical and clinical resistance profile of miravirsen, a novel anti-HCV therapeutic targeting the human factor miR-122.
    Ottosen S1, Parsley TB2, Yang L2, Zeh K3, van Doorn LJ4, van der Veer E4, Raney AK3, Hodges MR3, Patick AK5.
    Author information
    Abstract
    Miravirsen is a β-D-oxy-Locked Nucleic Acid modified phosphorothioate antisense oligonucleotide targeting the liver-specific microRNA-122 (miR-122). Miravirsen demonstrated antiviral activity against HCV genotype 1b replicons with a mean 50% effective concentration (EC50) of 0.67 μM. No cytotoxicity was observed up to the highest concentration tested (>320 μM) in different cell culture models yielding a therapeutic index of ≥297. Combination studies of miravirsen with interferon-α2b, ribavirin, non-nucleoside (VX-222) and nucleoside (2' -methylcytidine) inhibitors of NS5B, NS5A (BMS-790052), or NS3 (telaprevir) indicated additive interactions. Miravirsen demonstrated broad antiviral activity when tested against HCV replicons resistant to NS3, NS5A and NS5B inhibitors with less than 2-fold reductions in susceptibility. In serial passage studies, an A4C nucleotide change was observed in the 5' HCV UTR from cells passaged in the presence of up to 20 μM (40-fold the miravirsen EC50 concentration) at day 72 of passage but not at earlier time points (up to 39 days of passage). Likewise, a C3U nucleotide change was observed in the HCV 5' UTR from subjects with viral rebound after the completion of therapy in a miravirsen Phase 2 clinical trial. An HCV variant constructed to contain the A4C change was fully susceptible to miravirsen. A C3U HCV variant demonstrated overall reductions in susceptibility to miravirsen but was fully susceptible to all other anti-HCV agents tested. In summary, miravirsen has demonstrated broad antiviral activity and a relatively high genetic barrier to resistance. Identification of nucleotides changes associated with miravirsen resistance should help further elucidate the biology of miR-122 interactions with HCV. (The clinical trial study has been registered at ClinicalTrials.gov under registration no. NCT01200420).

    Copyright © 2014, American Society for Microbiology. All Rights Reserved.
    Nov 19, 2014. 07:57 PM | Likes Like |Link to Comment
  • Regulus To See Further Declines [View article]
    Results for one dose were excellent and it was the lower dose. Company never claimed one dose cure, nor anyone else of any standing or affiliation, but it may end up being the quickest cure. It's also possible it could be used in conjunction with another drug.
    Nov 19, 2014. 01:17 PM | Likes Like |Link to Comment
  • Regulus To See Further Declines [View article]
    For one ISIS sold only aprox 20% of their 7.1 million shares. Which always makes sense when you are funding a huge pipeline. You can debate market value after huge run up but remember this is a platform technology. MiR-122 will prove to be an extremely viable target.

    miR-122 Findings from Mt. Sinai
    http://bit.ly/11CzFxB

    >>Nov 18, 2014
    Hepatitis C Antiviral Resistance Revealed

    Scientists at the Icahn School of Medicine at Mount Sinai (ISMMS) say recent research has shed light on the response of the hepatitis C virus (HCV) to targeted therapeutics and provided new insights about HCV’s role in cancer development. Their work (“Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors”), published in Nature Communications, focused on microRNA genes, a type of regulatory gene, and used whole-genome sequencing of the virus to challenge conventional wisdom about how the virus responds to emerging therapies.

    Their findings, note the researchers, may contribute to more effective development of hepatitis C drugs in the future and to more personalized treatment for patients.

    According to the Centers for Disease Control and Prevention, HCV is widespread, affecting some 3% of the world’s population and more than 3 million people in the United States alone. Recent CDC reports indicate that hepatitis C infections are on the rise among young people and are increasingly the cause of death among baby boomers.

    The vast majority of people who get HCV will suffer chronic infection, which can lead to liver inflammation, cirrhosis, and liver cancer. Highly effective new treatments have been launched recently, but their high prices have caused public outcry and limited widespread use. There is no commercially available vaccine for hepatitis C.

    In this new study, Mount Sinai researchers examined HCV response to an experimental treatment that targets and blocks the supply of a microRNA (miR-122) that the virus needs for infection of human cells. Contrary to expectations, they found that depleting the supply of miR-122 could trigger drug resistance with the emergence of HCV strains able to infect cells with negligible levels of the microRNA. This information could be used for more effective dosing of drugs targeting this gene, as well as for pre-treatment analysis to determine which patients may respond best to this class of drugs.

    “This effort, which was made possible by innovative microRNA analysis, offers significant progress toward precision medicine in treating HCV patients,” said Matthew Evans, Ph.D., assistant professor of microbiology at the ISMMS and a co-author of the study. “There is a critical need for more weapons in our arsenal to fight HCV, particularly for affordable, effective treatment as we try to stay a step ahead of this virus and prevent it from developing the kind of drug resistance we’re seeing in the bacterial realm.”

    In another key finding, the scientists uncovered knowledge that may help answer the longstanding question of how HCV leads to cancer. The study demonstrated that HCV hijacks the miR-122 gene, diminishing its normal activity in liver cells. Since this microRNA is known to be a potent tumor repressor, it is possible that HCV robs cells of their natural defenses against uncontrolled growth. Such an outcome could contribute to cancers that arise from chronic HCV infection.

    “We found that HCV itself reduces miR-122’s activity in the cell, possibly through binding and sequestering miR-122,” wrote the investigators. “Our study provides insight into the interaction between miR-122 and HCV, including viral adaptation to reduced miR-122 bioavailability, and has implications for the development of anti-miR-122-based HCV drugs.”

    “Our study offers broader implications for this class of microRNA genes and their interaction with targets, which may be useful for a number of diseases in addition to hepatitis C,” said Brian Brown, Ph.D., associate professor of genetics and genomic sciences at the ISMMS and a co-author of the study. “We are also intrigued by this new information that may shed light on the link between HCV and the onset of cancer and look forward to future efforts to explore this theory.”<<
    Nov 19, 2014. 12:46 PM | Likes Like |Link to Comment
  • Genzyme and Isis Pharma announce presentation on cardiac benefits of Kynamro [View news story]
    MACE is the place! Results are unequivocal .
    Nov 18, 2014. 07:03 PM | 1 Like Like |Link to Comment
  • Isis earns milestone payment from GSK [View news story]
    It's the 4th drug with GSK and the 2nd undisclosed ocular drug. Undisclosed because ALNY and other RNA companies like to have ISIS do their drug target discovery for them.
    Nov 3, 2014. 12:23 PM | Likes Like |Link to Comment
  • Aegerion Pharmaceuticals misses by $0.06, misses on revenue [View news story]
    Things will get worse. ISIS AHA oral presentation - Decreased Cardiovascular Events in Familial Hypercholesterolemic Patients Treated With Mipomersen
    Sanofi reps are out in force.
    Oct 30, 2014. 04:38 PM | Likes Like |Link to Comment
  • Richmont Mines Has Tremendous Upside Potential Because Of Island Gold Deep [View article]
    Haven't read it all yet but excellent overview. Well done!
    Oct 30, 2014. 12:56 PM | Likes Like |Link to Comment
  • Regulus Therapeutics' RG-101 Poses Liver Cancer Risk [View article]
    Even if true, it's temporary, The HDLs will go back up when you stop the drug. A lot of things can cause cancer, it depends on the amount ingested or inhaled etc. but like cigarettes the risk is very low with short term use. And you are getting rid of permanent potentially fatal disease.
    Oct 23, 2014. 01:59 PM | 2 Likes Like |Link to Comment
  • Regulus Therapeutics' RG-101 Poses Liver Cancer Risk [View article]
    Where are your links showing a 30 to 40 % drop in HDLs? Lowering total cholesterol 30 to 40% is a good thing. Remember patients will not be taking the drug permanently and probably for a relatively short duration. Once the virus has been vanquished, you're done.
    Therefore, I strongly believe both issues you raise are way overblown.
    Oct 23, 2014. 12:45 PM | 7 Likes Like |Link to Comment
  • Isis - Addressing Some Of The Bull Arguments To My Short Thesis [View article]
    Videos don't lie. One of many children improving with SMNrx.
    http://bit.ly/TVNL8e
    Jul 10, 2014. 06:33 PM | Likes Like |Link to Comment
  • Isis - Addressing Some Of The Bull Arguments To My Short Thesis [View article]
    The complete fools at GSK just decided to continue to pay ISIS again to develop the HBV drug. Ever hear of the stat 3 drug? Nothing is guaranteed, but it just adds to the overwhelming evidence that BP believes the risk is worth the potential rewards.
    In June it was Biogen to develop a 4th drug. Obviously, that contradicts your whole short thesis ( as does just about everything else).
    But they aren't short stock or long puts.
    Jul 2, 2014. 12:11 PM | 2 Likes Like |Link to Comment
  • Isis: Long-Term Kynamro Adverse Events May Apply To Entire ISIS 2.0 Pipeline [View article]
    I believe SA should moderate what they allow to be published under their banner in particular a so called SA Pro where only a select group gets to know that a very slanted article is coming out that will increase the odds of a short term move up or down. I believe the SEC may want to look into this as well as the AGs. If you pay us you get to know that a baseless, inaccurate, article will be going public before it goes public,that says the company is probably going to beceome worthless? I think that runs afoul of SEC regs and more than one.
    Jun 27, 2014. 12:21 AM | 8 Likes Like |Link to Comment
COMMENTS STATS
355 Comments
339 Likes